Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90001 in NASH with Liver Fibrosis
NCT04048876Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of CC-90001 in Nonalcoholic steatohepatitis (NASH), Liver Fibrosis (LF), sponsored by Celgene Corporation. Started Aug 2019; status: terminated.
02
Drugs
CC-90001
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT04048876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048876.